Ivo D.
- Country
- Czechia
- Department
- Klinika hematoonkologie FNO a LF OUFN Ostrava
Research Overview
- Efficacy and Safety Evaluation of Efgartigimod Alfa in Adults with Primary Immune Thrombocytopenia: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- A multi-center, open-label, single-arm study to evaluate the efficacy and safety of oral rilzabrutinib in adults with immune thrombocytopenia (ITP) who failed first-line treatment
Data & Insights
Has run more than one trial at 13 of 84 partner sites.
Specializations
Hematological Disorders
The investigator specializes in the study and treatment of primary immune thrombocytopenia (ITP), a rare autoimmune blood disorder characterized by low platelet counts.
- Autoimmune Blood Disorders
- Platelet Disorders
- Immune System Dysfunction
Their research extends to evaluating novel therapeutic approaches for managing platelet counts and improving disease control in adult patients with ITP.
Immunology
The investigator focuses on immunological interventions in blood disorders, particularly exploring innovative antibody-based treatments.
- Immunoglobulin Research
- Autoimmune Disease Management
- Novel Therapeutic Approaches
Their work encompasses the evaluation of targeted immunological therapies for managing autoimmune conditions affecting blood components.
Clinical Applications
The investigator's expertise includes therapeutic development for rare hematological conditions, with emphasis on safety and efficacy assessment.
- Treatment Optimization
- Disease Control Strategies
- Patient Response Assessment
Their research contributes to advancing treatment options for patients with challenging hematological disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.